Naproxen Label Shows Limitations Of Class Effect Thinking – Harvard’s Avorn

The inclusion of naproxen in NSAID cardiovascular warning label requirements is an overextension of the use of "class effect" labeling, pharmacoepidemiologist Jerry Avorn, Harvard University, said